Clinical trials are also anticipated to repurpose tocilizumab, a clinically approved drug used for the treatment of autoimmune diseases such as arthritis, to improve the prognosis of patients with cancers displaying CIN and activated IL-6-STAT3 signaling. Here, STAT3 is linked to cervical squamous intraepithelial neoplasia.